Generic Name and Formulations:
Mometasone furoate 0.1%; crm; oint.
Merck & Co., Inc.
Indications for ELOCON:
Adults and Children:
<2yrs: not recommended. ≥2yrs: apply thin film once daily; max 3 weeks' therapy for children. Discontinue when control is achieved. Do not occlude.
Avoid use near eyes, on face, groin, or axillae. Do not use for diaper dermatitis. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, or reduce dose or potency if occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Treat infection if present; discontinue if infection persists or worsens. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Burning, pruritus, skin atrophy, tingling/stinging, furunculosis, acneiform reaction, folliculitis; allergic contact dermatitis (discontinue if irritation occurs), HPA axis suppression (esp. in children); rare: Cushing's syndrome, hyperglycemia.
Oint—15g, 45g; Crm—15g, 50g; Lotion—30mL, 60mL